Most community protocols start cagrilintide at 0.25 mg/week once tirzepatide is established, then step up every 4 weeks to 0.5, 1.0, 1.7, and 2.4 mg/week
Individuals with significant body weight to lose, typically those with a BMI that qualifies for GLP-1 therapy and who have 30% or more body weight to lose, may benefit from the more aggressive metabolic intervention this combination provides
therefore, it must be transported into the cells by SLC7A11 (xCT) in exchange for glutamate, which implies that SLC7A11-mediated GSH biosynthesis largely relies on glutamine metabolism 55
This leads to fewer cravings, satisfaction with smaller portions, and resulting weight loss
There may be differences between animal and human results
Either way, there will be people who will want to use these medications (perhaps even you) so here are some takeaways to consider before you do: How to Minimize Your Risk of Side Effects & Maximize the Benefits #1